Basic information Safety Supplier Related

Actoxumab

Basic information Safety Supplier Related

Actoxumab Basic information

Product Name:
Actoxumab
Synonyms:
  • Actoxumab
  • Research Grade Actoxumab(DXX00201)
  • Research Grade Actoxumab
  • Actoxumab (anti-Cdiff Toxin A)
CAS:
1245634-25-6
MW:
0
Mol File:
Mol File
More
Less

Actoxumab Chemical Properties

form 
Liquid
color 
Colorless to light yellow
More
Less

Actoxumab Usage And Synthesis

Uses

Actoxumab (Anti-C. difficile Toxin A Recombinant Antibody) is a antitoxin antibody against C. difficile toxin A by neutralizing TcdA. Actoxumab prevents both the damage to the gut wall and the inflammatory response, which are associated with C. difficile. Actoxumab has synergy effect with Bezlotoxumab.html" class="link-product" target="_blank">Bezlotoxumab (HY-P9929) targeting TcdB[1].

in vivo

Actoxumab (0.1-10 mg/kg or 50 mg/kg; i.p.; single dose) shows protective effect in multiple murine models of clostridium difficile infection (CDI), including systemic and local (gut) toxin challenge models, as well as primary and recurrent models of infection in mice[1].
Actoxumab shows a synergy with Bezlotoxumab, and (combination dosage of 3, 30, 300 μg/mouse; i.p.; single dose) prevents both epithelial damage and inflammatory disease[1].

Animal Model:Murine C. difficile infection model in CD1 and C57BL/6 mice (6-8 weeks old)[1]
Dosage:Combination dosage of 3, 30, 300 μg/mouse; or ~0.1, 1, and 10 mg/kg
Administration:Intraperitoneal injection; single dose; 1 hour before 25 ng TcdA or 25 ng TcdB challenge
Result:Protected with Bezlotoxumab, against systemic and intestinal toxin challenge in mice.
Animal Model:Ileal loop model in CD1 and C57BL/6 mice (6-8 weeks old)[1]
Dosage:50 mg/kg; or combined with 50 mg/kg Bezlotoxumab
Administration:Intraperitoneal injection; single dose
Result:Significantly reduced fluid accumulation in toxin-challenged mice (109.4 mg/cm).

References

[1] Yang Z, et al. Mechanisms of protection against Clostridium difficile infection by the monoclonal antitoxin antibodies actoxumab and bezlotoxumab. Infect Immun. 2015 Feb;83(2):822-31. DOI:10.1128/IAI.02897-14

ActoxumabSupplier

BOC Sciences
Tel
1-631-485-4226; 16314854226
Email
info@bocsci.com
Shanghai YuanYe Biotechnology Co., Ltd.
Tel
021-61312847; 18021002903
Email
3008007409@qq.com
ShangHai Biochempartner Co.,Ltd
Tel
177-54423994 17754423994
Email
2853530910@QQ.com
Guangzhou Hongyuan Chemical Co.,Ltd
Tel
15817493340
Email
981810490@qq.com
Wuhan Chemstan Biotechnology Co., Ltd.
Tel
027-65317797 15926423062
Email
422450190@qq.com
More
Less

Actoxumab(1245634-25-6)Related Product Information